Search

everythinglearnresearchcommunity

for

Search:↓

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Upadacitinib cleared scalp alopecia areata in three patients and also improved atopic dermatitis with minimal side effects.

Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.

Tofacitinib may help treat severe hair loss, but more research is needed.

More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.

Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.

Tofacitinib may help treat hair loss in children with alopecia areata.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Upadacitinib may effectively treat alopecia areata without side effects.

Afatinib can cause eyelash and eyebrow issues, leading to eye irritation and pain.

Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

The drug combination was safe and showed promise in treating advanced tumors.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.